



Mr. Rajin Ahuja
Chairman

Board Introductions

- Rajin Ahuja
- Thomas Roberg
- Dr Laura Calamos
- Dr Brian Dickson
- Dr Walker Long
- Dr Ashish Bhatia
- Craig Collard
- Amit Shah

Chairman

Vice Chairman



Clinical Studies

Non Small Cell Lung Cancer (NSCLC)

Acute Respiratory Distress Syndrome (ARDS)

NSCLC

- Advanced (metastatic) lung cancer
- Untreated; 8 month survival
- 17%, five year survival
- Standard of Care (SOC), Carboplatin and Pemetrexed
- Quality of Life (QOL)
- Keytruda, immunotherapy

NSCLC Results to Date

- **No Progression** (tumor bigger/more metastases)

- At 3 months

- At 6 months

- SOC 73%

- SOC 67%

- SOC + BIO-11006 93%

- SOC + BIO-11006 77%

- **Partial Response** (tumor 30% smaller/no more metastases)

- At 3 months

- SOC 8%

- SOC + BIO-11006 27%


ARDS

- Sudden massive neutrophil influx to lungs
- Cytokine Storm
- 40% - 50% die within 30 days
- Only approved treatment is a ventilator in ICU

ARDS Clinical Study

- All patients on ventilator
- Patients randomize (1:1) to BIO-11006 or placebo
- Mortality at 30 days is primary endpoint
- 5 Investigator Sites in US (UNC, Chicago, Penn, Vanderbilt, WF)
- Same sites had 47% mortality in 12 months prior to study
- Current study has 25% mortality (25 of 40 patients enrolled)

ARDS 30 Day Mortality Phase 2 Clinical Study (Treatment of Established ARDS Patients)





Questions and Close